How to Get Mounjaro Without Diabetes: The Legitimate Pathways in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 12 sources cited

Key Takeaways

• Mounjaro is FDA-approved only for type 2 diabetes. A prescriber cannot legally write Mounjaro for weight loss in most circumstances, and most insurance plans will deny it.
• The same molecule, tirzepatide, is FDA-approved for chronic weight management under the brand name Zepbound. That's the on-label path for adults without diabetes.
• Compounded tirzepatide is a separate pathway. It requires a clinical evaluation, a state-licensed compounding pharmacy, and a documented patient-specific reason to use a compounded preparation.
• Off-label Mounjaro prescribing for weight loss does happen, but it usually means full cash price ($1,000 to $1,300 per month) and increased prior-authorization scrutiny.
• BMI of 30 or higher, or 27 or higher with a weight-related condition, is the standard eligibility threshold for Zepbound and most weight-management programs.

Direct answer (40-60 words)

To get tirzepatide without a diabetes diagnosis in 2026, the on-label path is a Zepbound prescription, which is FDA-approved for chronic weight management at BMI 30 or higher, or 27 or higher with a weight-related condition. Compounded tirzepatide through a licensed pharmacy is a separate pathway. Off-label Mounjaro for weight loss is generally cash-pay and harder to insure.

Table of contents

1. Why Mounjaro is "diabetes-only" on the label
2. Zepbound: the same drug, the on-label answer
3. Eligibility thresholds for tirzepatide without diabetes
4. Pathway 1: getting Zepbound through commercial insurance
5. Pathway 2: getting Zepbound cash-pay (LillyDirect)
6. Pathway 3: compounded tirzepatide through telehealth
7. Off-label Mounjaro: when it happens and what it costs
8. Prior-authorization documentation that actually works
9. Red flags: what to avoid
10. FAQ

Why Mounjaro is "diabetes-only" on the label

Mounjaro and Zepbound are the same molecule, tirzepatide, made by the same manufacturer, Eli Lilly. The FDA approved Mounjaro in May 2022 for type 2 diabetes. It approved Zepbound in November 2023 for chronic weight management. Lilly chose to brand the two indications separately so that pharmacy benefits, insurance formularies, and clinical guidelines could treat them as distinct products.

In practice, this means:

• A prescription written for "Mounjaro" is processed as a diabetes medication.
• A prescription written for "Zepbound" is processed as a weight-loss medication.
• Insurance plans that cover Mounjaro for diabetes often refuse to cover it when the diagnosis on the prescription is obesity or overweight.
• Pharmacies will fill a Mounjaro prescription regardless of diagnosis, but the patient is the one who pays the gap.

The clinical evidence for tirzepatide in weight loss is the same drug, the same dose, and largely the same data. SURMOUNT-1 (Jastreboff et al., NEJM 2022) showed average weight loss of about 20.9 percent at the 15 mg dose over 72 weeks in adults without diabetes. The label split is a regulatory and commercial choice, not a clinical one.

If your goal is weight loss and you don't have diabetes, the conversation you want with a prescriber is about Zepbound or compounded tirzepatide, not about Mounjaro.

Zepbound: the same drug, the on-label answer

Zepbound is tirzepatide approved for adults with:

• BMI of 30 or higher (obesity), or
• BMI of 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease).

The dose ladder is identical to Mounjaro: 2.5 mg for weeks 1 through 4, then 5 mg, with monthly escalations to 7.5, 10, 12.5, and 15 mg as tolerated. The injection is once weekly, subcutaneous, in a single-dose pen.

In SURMOUNT-1, adults without diabetes treated with tirzepatide for 72 weeks lost on average:

• 15.0 percent of body weight at 5 mg
• 19.5 percent at 10 mg
• 20.9 percent at 15 mg
• vs 3.1 percent on placebo

In SURMOUNT-2 (Garvey et al., Lancet 2023), adults with type 2 diabetes and obesity lost on average 12.8 to 14.7 percent across the 10 and 15 mg doses, lower than SURMOUNT-1 because diabetes blunts weight-loss response somewhat.

If you qualify by BMI, Zepbound is the most direct pathway. There's no clinical reason to chase Mounjaro instead.

Eligibility thresholds for tirzepatide without diabetes

The standard thresholds for any prescriber considering tirzepatide for weight loss in adults without diabetes:

BMI	Comorbidity required	Pathway
30 or higher	None	Zepbound (on-label) or compounded tirzepatide
27 to 29.9	At least one weight-related condition (hypertension, dyslipidemia, OSA, CVD, prediabetes)	Zepbound (on-label) or compounded tirzepatide
25 to 26.9	Multiple metabolic conditions plus prescriber judgment	Off-label only, cash-pay typical
Below 25	Not appropriate	None

BMI is calculated as weight in kilograms divided by height in meters squared. An online BMI calculator works fine. Your prescriber will document your starting BMI in the chart and on the prior-authorization form.

A few notes on comorbidities for the BMI 27-29.9 group:

• Prediabetes (A1c 5.7 to 6.4 percent) counts on most plans.
• Hypertension counts whether or not you're on medication.
• Dyslipidemia (high LDL, high triglycerides, low HDL) counts if documented.
• Polycystic ovary syndrome (PCOS) counts on some plans, not others.
• Non-alcoholic fatty liver disease (NAFLD or MASLD) is increasingly accepted.
• Self-reported sleep apnea without a sleep study usually doesn't count.

Pathway 1: getting Zepbound through commercial insurance

Commercial insurance is the cheapest path if your plan covers Zepbound. As of 2026, an estimated 30 to 40 percent of commercial plans cover Zepbound with prior authorization, up from roughly 25 percent in 2024 per ICER and AHIP tracking.

The standard sequence:

1. Confirm your plan covers Zepbound. Search your formulary for "tirzepatide" or "Zepbound." Look for the tier and the prior-authorization (PA) flag.
2. Schedule a visit with a prescriber. This can be a primary care doctor, an obesity-medicine specialist, or a telehealth platform that prescribes Zepbound.
3. Document medical necessity. Bring records: BMI, blood pressure, A1c, lipid panel, prior weight-loss attempts (Weight Watchers, MyFitnessPal logs, prior medications), and any comorbid conditions.
4. Submit the PA. Your prescriber's office submits the PA to the insurance plan. Most plans require:

• Diagnosis of obesity (BMI 30+) or overweight with comorbidity (BMI 27+)
• Documentation of at least 6 months of supervised lifestyle intervention
• Prior trial of at least one other weight-loss medication, sometimes

1. Wait for the determination. PAs take 3 to 14 days. Approvals are typically valid for 6 to 12 months and require documented progress (5 percent weight loss by month 6, often) for renewal.
2. Fill at any pharmacy. Bring the Zepbound Savings Card from Lilly (commercial-insurance patients only). Eligible patients pay as little as $25 to $549 per month depending on whether the plan covers Zepbound.

Approval rates vary widely. A 2024 GoodRx survey found 47 percent of GLP-1 prescriptions required PA, and 22 percent were denied on first submission. Appeals overturn roughly half of denials when supporting documentation is strong.

Pathway 2: getting Zepbound cash-pay (LillyDirect)

For patients without insurance coverage for Zepbound, Lilly launched LillyDirect (the Zepbound Self-Pay program) in 2024. It sells single-dose vials of Zepbound at a discount versus the pen.

As of Q1 2026, LillyDirect Self-Pay pricing for vials:

• 2.5 mg vials: about $349 per month
• 5 mg vials: about $499 per month
• 7.5 mg vials: about $599 per month
• 10 mg vials: about $699 per month

The pen versions, also through LillyDirect, are priced higher (closer to standard cash price of $1,000 to $1,100 per month).

The vial requires the patient to draw the dose into a U-100 insulin syringe. It's the same medication as the pen, just a different delivery method.

Eligibility for LillyDirect Self-Pay:

• U.S. resident
• Valid Zepbound prescription
• Not using insurance to pay
• Provides credit-card payment

This pathway works for patients who don't qualify by BMI for insurance coverage but want the brand-name product, or whose insurance simply excludes Zepbound.

Pathway 3: compounded tirzepatide through telehealth

When the FDA Drug Shortage List included tirzepatide (March 2024 through December 2024), state-licensed compounding pharmacies could prepare tirzepatide under section 503A of the FD&C Act. The shortage was officially resolved in late 2024 with a wind-down period that ended in 2025, but compounded tirzepatide remains available in narrow circumstances:

• The patient cannot use the FDA-approved formulation for documented clinical reasons (allergy to an excipient, need for a custom dose, etc.)
• The compound is patient-specific, prescribed by a licensed provider after evaluation
• The compounding pharmacy is state-licensed (503A) or FDA-registered (503B)

Compounded tirzepatide pricing through telehealth typically runs $279 to $499 per month with no insurance involvement. The cost difference vs Zepbound at LillyDirect is real, but the regulatory framework is more constrained than during the shortage period.

What patients should look for in a compounding telehealth provider:

• A licensed clinician evaluation, not a one-question intake form
• Documented BMI and comorbidity assessment
• A 503A or 503B pharmacy partner with a verifiable license
• Tirzepatide as the active ingredient, not an unverified analog
• Clear labeling of concentration (mg/mL) on the vial

What to avoid:

• Sites selling "tirzepatide" with no prescription required
• "Research chemicals" sold without a clinician
• Pricing far below market ($150 or less per month is a red flag)
• Shipments from outside the U.S.

A 2024 Senate HELP Committee report on compounded GLP-1s noted that the most consistent issue across complaints was inconsistent labeling (mg vs mg/mL confusion) rather than the active ingredient itself.

Off-label Mounjaro: when it happens and what it costs

Some prescribers will write Mounjaro for weight loss in a patient without diabetes. This is legal off-label prescribing in the United States. It's not regulatory misconduct.

What changes for the patient:

• Insurance is unlikely to cover it. Most plans require a diabetes diagnosis (E11 ICD-10 codes) for Mounjaro coverage. A diagnosis of obesity (E66) on a Mounjaro claim usually triggers automatic denial.
• Cash price is full retail. Walmart, CVS, Costco cash prices for Mounjaro in Q1 2026 run $1,000 to $1,300 per month.
• The Lilly Savings Card for Mounjaro requires a diabetes diagnosis. Patients without diabetes can't use it.
• Pharmacies will fill the prescription. A Mounjaro prescription written by a licensed prescriber is fillable. The pharmacy doesn't audit the diagnosis.

There are very few situations where chasing off-label Mounjaro makes sense over Zepbound. Same molecule, same dose, same delivery, same price ceiling. The only common reason is supply: at moments when Zepbound has been temporarily backordered at certain doses, off-label Mounjaro has filled the gap.

Prior-authorization documentation that actually works

For Zepbound PAs (the much more common path for patients without diabetes), strong documentation typically includes:

• Current BMI. Calculated from documented height and weight, ideally measured in clinic.
• Comorbidity diagnoses. Hypertension, dyslipidemia, prediabetes, OSA, NAFLD, PCOS, etc., with ICD-10 codes.
• Weight history. A 1 to 5 year weight trajectory if available.
• Prior interventions. Six months or more of documented lifestyle intervention (typically a weight-management program, dietitian visits, or a structured plan) and any prior anti-obesity medications tried (phentermine, topiramate, naltrexone-bupropion, semaglutide, liraglutide).
• Contraindications screened. No personal or family history of medullary thyroid carcinoma, no MEN 2 syndrome, no known hypersensitivity.
• Proposed regimen. Starting at 2.5 mg weekly with the standard escalation schedule.

PA forms vary by plan but the substance is consistent. Plans that cover Zepbound usually want documented evidence of medical necessity, not just a checked box.

A 2025 JAMA Network Open analysis of GLP-1 PA outcomes found that patients with BMI above 35 and at least 2 documented comorbidities had a 78 percent first-pass approval rate, vs 41 percent for patients with BMI 27 to 30 and a single comorbidity.

Red flags: what to avoid

Patients searching for tirzepatide without a diabetes diagnosis sometimes encounter risky pathways. The signals that should make you walk away:

• No prescription required. Tirzepatide is a prescription medication in the U.S. Sites selling it without a clinician evaluation are operating outside the law and outside any meaningful clinical oversight.
• "Research chemical" framing. "Not for human consumption" labeling on a peptide is a legal disclaimer used to sidestep prescription requirements. Injecting research chemicals carries unknown sterility, purity, and dosing risks.
• International shipping. Importing prescription drugs by mail violates federal law and puts the patient at risk of seized shipments, counterfeits, and unverified contents.
• Vague active ingredient. "Tirzepatide blend" or "tirzepatide + B12 + L-carnitine" combinations sold without a documented prescription are typically compounded for marketing reasons rather than clinical ones.
• Pricing far below market. Quality compounded tirzepatide costs the pharmacy real money to prepare. Sites pricing it at $99 per month should raise the question of where the cost-cutting happened.
• No license disclosure. Legitimate compounding pharmacies are licensed in every state where they ship. The license number should be findable.

The cheapest legitimate path for an uninsured patient without diabetes in 2026 is usually LillyDirect Self-Pay vials at $349 to $699 per month, or compounded tirzepatide through a verified telehealth platform at $279 to $499 per month. Anything significantly cheaper than that warrants extra scrutiny.

FAQ

Can I get Mounjaro if I don't have diabetes? Technically yes, through off-label prescribing, but most insurance plans deny coverage and the cash price is $1,000 to $1,300 per month. The on-label option for adults without diabetes is Zepbound, which contains the same molecule (tirzepatide) and is FDA-approved for weight management at BMI 30 or higher (or 27 or higher with a weight-related condition).

What's the difference between Mounjaro and Zepbound? They're the same drug (tirzepatide) made by the same manufacturer (Eli Lilly). Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for weight management. The dose, schedule, and pen design are essentially identical. The brand split exists for regulatory and insurance-formulary reasons.

Do I need a BMI of 30 to get tirzepatide? For on-label Zepbound, you need a BMI of 30 or higher, or 27 or higher with at least one weight-related condition (hypertension, dyslipidemia, prediabetes, OSA, cardiovascular disease, NAFLD, PCOS in some plans). Below BMI 27, on-label use is not generally appropriate.

Will insurance cover Zepbound for weight loss? About 30 to 40 percent of commercial plans cover Zepbound with prior authorization in 2026. Medicare does not cover Zepbound for weight loss (Medicare statute prohibits coverage of weight-loss drugs). Medicaid coverage varies by state. Always check your formulary.

How much does Zepbound cost without insurance? Through LillyDirect Self-Pay vials: about $349 to $699 per month depending on dose. Through retail pharmacies: $1,000 to $1,100 per month for the pen. Compounded tirzepatide through telehealth: $279 to $499 per month.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient. It is not FDA-approved and is not interchangeable with Zepbound. It's prepared by a state-licensed compounding pharmacy in response to an individual prescription, often as a vial drawn with an insulin syringe rather than a pen.

Can a primary care doctor prescribe tirzepatide for weight loss? Yes. Any licensed prescriber (MD, DO, NP, PA depending on state) can prescribe Zepbound or write off-label scripts. Specialist obesity-medicine clinicians have more PA experience and may have higher first-pass approval rates.

What documentation do I need for a Zepbound prior authorization? Current BMI, comorbidity diagnoses with ICD-10 codes, 6 months of documented lifestyle intervention, prior weight-loss medications tried, and screening for contraindications (no medullary thyroid carcinoma history, no MEN 2 syndrome). Strong documentation roughly doubles first-pass approval rates per published claims data.

Is it legal to import tirzepatide from overseas? No. The FDA prohibits personal importation of unapproved prescription drugs. Imported tirzepatide also carries risks of counterfeit product, unverified concentration, and seized shipments.

Can I switch from Mounjaro to Zepbound? Yes. The dose and schedule are the same. A new prescription written as Zepbound at the dose you're currently tolerating is the standard transition. Confirm with your prescriber and pharmacy.

What if my BMI is 25 to 26.9 and I want tirzepatide? On-label coverage is unlikely. A clinician may prescribe off-label in select cases (significant metabolic comorbidities, family history, prior weight gain), but expect cash-pay pricing and most plans to deny. Lifestyle, dietitian support, and other anti-obesity medications may be more practical at this BMI.

Does the Lilly Savings Card work for patients without diabetes? The Mounjaro Savings Card requires a type 2 diabetes diagnosis. The Zepbound Savings Card is for commercial-insurance patients with a Zepbound prescription. Patients without diabetes use the Zepbound card, not the Mounjaro one.

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
3. U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company, 2024.
4. U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. Eli Lilly and Company, 2024.
5. U.S. Food and Drug Administration. Drug Shortage List, archived entry: tirzepatide injection. Updated December 2024.
6. U.S. Senate Committee on Health, Education, Labor and Pensions. Report on Compounded GLP-1 Medications. 2024.
7. GoodRx Research. Prior Authorization Trends for GLP-1 Medications. 2024.
8. Institute for Clinical and Economic Review (ICER). Anti-Obesity Medications Coverage Update. 2025.
9. America's Health Insurance Plans (AHIP). Commercial Coverage of GLP-1 Therapies, Tracking Brief. 2025.
10. Watanabe JH, Kwon J, Nan B, et al. Trends in prior authorization outcomes for GLP-1 receptor agonists. JAMA Network Open. 2025;8(2):e2455123.
11. Centers for Disease Control and Prevention. Defining Adult Overweight and Obesity. 2024.
12. National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight and Obesity. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.